


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 16/00	A2	(11) International Publication Number: WO 98/45332 (43) International Publication Date: 15 October 1998 (15.10.98)
<p>(21) International Application Number: PCT/US98/06724</p> <p>(22) International Filing Date: 3 April 1998 (03.04.98)</p> <p>(30) Priority Data: 08/833,504 7 April 1997 (07.04.97) US</p> <p>(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): WELLS, James, A. [US/US]; 1341 Columbus Avenue, Burlingame, CA 94010 (US). BACA, Manuel [AU/US]; Apartment #H3, 888 Foster City Boulevard, Foster City, CA 94404 (US). PRESTA, Leonard, G. [US/US]; Apartment 206, 1900 Gough, San Francisco, CA 94109 (US).</p> <p>(74) Agents: DREGER, Walter, H. et al.; Flehr, Hohbach, Test, Albritton & Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>	

(54) Title: HUMANIZED ANTIBODIES AND METHODS FOR FORMING HUMANIZED ANTIBODIES


(57) Abstract

Described herein is a humanized antibody to vascular endothelial growth factor (VEGF). Also described herein is a method for rapidly producing and identifying framework mutations which improve the binding of humanized antibodies to their cognate antigens. In a preferred embodiment, non-human CDRs are grafted onto a human V₁κI-V_HIII framework. Random mutagenesis of a small set of critical framework residues is also performed followed by monovalent display of the resultant library of antibody molecules on the surface of filamentous phage. The optimal framework sequences are then identified by affinity-based selection. Optionally, the selected antibodies can be further mutated so as to replace vernier residues which sit at the V_L-V_H interface by residues which match the non-human parent antibody. The methods described herein can be applied to any non-human antibody. Accordingly, humanized antibodies are provided.

TRANSFORM *E. coli*

+M13KO7 HELPER PHAGE

FAB-pIII FUSION



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMANIZED ANTIBODIES AND METHODS FOR FORMING HUMANIZED ANTIBODIES

FIELD OF THE INVENTION

The present invention is directed at humanized antibodies and methods for preparing humanized antibodies. In particular, the present invention is directed at methods for preparing humanized antibodies using a monovalent phage display system and antibody mutants produced by random mutagenesis of a small set of critical framework residues made to a single human framework. More particularly, this invention is directed at the humanization of a murine antibody which binds to vascular endothelial growth factor (VEGF).

BACKGROUND OF THE INVENTION

Monoclonal antibodies (mAbs) have enormous potential as therapeutic agents, particularly when they can be used to regulate defined systems. For example, in some circumstances it would be desirable to regulate a system such as angiogenesis, where new blood capillaries are formed from the walls of existing small vessels. Angiogenesis is generally important after infliction of a wound or infection so that a burst of capillary growth can be stimulated in the neighborhood of the damaged tissue. However, angiogenesis is also important in tumor growth since, for continued growth, a tumor must induce the formation of a capillary network that invades the tumor mass.

Certain growth factors have been identified which regulate angiogenesis. Of particular interest is the vascular endothelial growth factor (VEGF), which seems to be the agent by which some tumors acquire their rich blood supply. Molecular Biology of the Cell, 3rd Ed., Alberts et al., Garland Publishing, page 1154 (1994). Therefore, mAbs to VEGF, for example, can be useful for a variety of reasons, including for use in the regulation of angiogenesis and more particularly, as an anti-tumor agent. A murine anti-VEGF mAb A4.6.1 which blocks VEGF receptor binding has been previously described. This antibody has been shown to inhibit mitogenic signaling. Kim et al., *Growth Factors* 7, 53 (1992); Kim et al., *Nature* 362, 841 (1993).

Most mAbs including the anti-VEGF described above are derived from murine or other non-human sources which limits clinical efficacy. In particular, the body often reacts with an immunogenic response to non-human antibodies whereby the antibody is rapidly cleared from the system before any therapeutic effect can occur. In addition to the immunogenicity of non-human mAbs invoked when administered to humans, further limitations arise from weak recruitment of effector function.

As a means of circumventing these deficiencies, the antigen binding properties of non-human mAbs can be conferred to human antibodies through a process known as antibody "humanization". A humanized antibody contains the amino acid sequence from the six complementarily-determining regions (CDRs) (the antigen-binding site of the antibody molecule) of the parent or corresponding non-human mAb, grafted onto a human antibody framework. Therefore, humanization of non-human antibodies is commonly referred to as CDR grafting. The low content of non-human sequence in such humanized antibodies (~5%) has proven effective in reducing the immunogenicity and prolonging the serum half-life of the antibodies administered to humans. Inter alia, humanized monoclonal antibodies ("chimeric immunoglobulins") are disclosed in U.S. Patent No. 4,816,567.

Unfortunately, simple grafting of CDR sequences often yields humanized antibodies which bind antigen much more weakly than the parent non-human mAb. In order to restore high affinity, the antibody must be further engineered to fine-tune the structure of the antigen binding loops. This is achieved by replacing key residues in the framework regions of the antibody variable domains with the matching sequence from the parent murine antibody. These framework residues are usually involved in supporting the conformation of the CDR loops, although some framework residues may themselves directly contact the antigen. Studies have been conducted which note the importance of certain framework residues to CDR conformation and a comprehensive list of all the framework residues which can affect antigen binding has been compiled. Chothia et al., *J. Mol. Biol.* 224, 487 (1992); Foote et al., *J. Mol. Biol.* 224, 489 (1992). The comprehensive list includes some thirty "vernier" residues which can potentially contribute to CDR structure. Although higher antigen affinity would likely result from editing the entire set of vernier residues within a humanized antibody so as to match the corresponding parent non-human sequence, this is not generally desirable

given the increased risk of immunogenicity imposed by adding further elements of non-human sequence. Thus, from a therapeutic standpoint, it is preferable to confine framework changes to the minimum set which affords a high affinity humanized antibody.

- 5 Therefore, it is desirable to identify a small set of changes which suffice to optimize binding, however, the required changes are expected to differ from one humanized antibody to the next. To achieve the desired result, one approach has been to identify the proper combination of mutations by constructing a panel of mutants having "suspect" framework residues replaced by their murine counterpart. These variants are each individually formed
- 10 and tested for antigen and then combined with other variants found to have favorable binding affinities. However, this method involves cycles of individual site-directed mutagenesis, isolation and screening, and is therefore undesirable because it is time consuming and tedious.
- 15 As a means of simplifying antibody humanization, a number of different approaches have been developed. See, for example, Queen et al., *PNAS USA* 86, 10029 (1989); Kettleborough et al., *Protein Eng.* 4, 773 (1991); Tempest et al., *Biotechnology* 9, 266 (1991); Padlan, *Mol. Immunol.* 28, 489 (1991); Roguska et al., *PNAS USA* 91, 969 (1994); Studnicka et al., *Protein Eng.* 7, 805 (1994); Allen et al., *J. Immunol.* 135, 368 (1985);
- 20 Carter et al., *PNAS USA* 89, 4285 (1992); Presta et al., *J. Immunol.* 151, 2623 (1993); Eigenbrot et al., *Proteins* 18, 49 (1994); Shalaby et al., *J. Exp. Med.* 175, 217 (1992); Kabat et al., Sequences of Proteins of Immunological Interest, (5th), Public Health Service, NIH, Bethesda, MD (1991); and Rosok et al., *J. Biol. Chem.* 271, 22611 (1996).

It is an object of the present invention to provide a general means of rapidly selecting

25 framework mutations which improve the binding of humanized antibodies to their cognate antigens wherein the current methods of framework optimization based on cycles of individual site-directed mutagenesis and screening are eliminated.

It is also an object to provide rapid methods of humanizing antibodies which provide

30 antibodies with low immunogenicity and which utilize a single human framework as a generic scaffold.

It is a further object of the present invention to provide humanized antibodies which are mutated to have enhanced affinity for antigen relative to the initial humanized antibody with no framework changes.

- 5 It is additionally a further object of the present invention to provide humanized antibodies that have a reduced clearance rate and hence longer retention within the body after systemic administration such that lower doses of the material are available for systemic administration for therapeutic effect.
- 10 It is also a further object of the present invention to provide humanized monoclonal antibodies to VEGF.

SUMMARY OF THE INVENTION

- The present invention provides a humanized antibody to vascular endothelial growth factor (VEGF). The initial humanized anti-VEGF has a framework derived from consensus sequences of the most abundant human subclasses, namely $V_L\kappa$ subgroup I ($V_L\kappa I$) and V_H subgroup III ($V_H III$) wherein the CDRs from non-human anti-VEGF are grafted thereon. Random mutagenesis of critical framework residues on the initial construct produced the humanized anti-VEGF described herein which has 125 fold enhanced affinity for antigen relative to the initial humanized antibody with no framework changes. A single additional mutation gave a further six fold improvement in binding. This humanized anti-VEGF can be reproduced by the method described herein or by traditional recombinant techniques given the sequence information provided herein.
- 25 Also provided herein is a method for rapidly producing and identifying framework mutations which improve the binding of humanized antibodies to their cognate antigens. In a preferred embodiment, non-human CDRs are grafted onto a human $V_L\kappa I$ - $V_H III$ framework. Random mutagenesis of a small set of critical framework residues is also performed followed by monovalent display of the resultant library of antibody molecules on the surface of filamentous phage. The optimal framework sequences are then identified by affinity-based selection. Optionally, the selected antibodies can be further mutated so as to replace vernier
- 30

residues which sit at the V_L - V_H interface with residues which match the non-human parent antibody.

The methods described herein can be applied to any non-human antibody. Accordingly,
5 humanized antibodies are provided by the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the amino acid sequences of murine A4.6.1 (SEQ ID NO: 6 and 9 for the V_L and V_H domains, respectively), humanized A4.6.1 variant hu2.0, (SEQ ID NO: 7 and 10
10 for the V_L and V_H domains, respectively), and humanized A4.6.1 variant hu2.10 (SEQ ID NO: 8 and 11 for the V_L and V_H domains, respectively). Sequence numbering is according to Kabat et al., Sequences of Proteins of Immunological Interest, (5th), Public Health Service, NIH, Bethesda, MD (1991) and mismatches are indicated by asterisks (murine A4.6.1 vs hu2.0) or bullets (hu2.0 vs hu2.10). Variant hu2.0 contains only the CDR
15 sequences (bold) from the murine antibody grafted onto a human light chain K subgroup I, heavy chain subgroup III framework. Variant hu2.10 is the consensus humanized clone obtained from phage sorting experiments described herein.

Figure 2 depicts the framework residues targeted for randomization.

20

Figure 3 depicts the phagemid construct for surface display of Fab-pIII fusions on phage. The phagemid construct encodes a humanized version of the Fab fragment for antibody A4.6.1 fused to a portion of the M13 gene III coat protein. The fusion protein consists of the Fab joined at the carboxyl terminus of the heavy chain to a single glutamine residue (from
25 suppression of an amber codon in supE *E. coli*), then the C-terminal region of the gene III protein (residues 249-406). Transformation into F^+ *E. coli*, followed by superinfection with M13KO7 helper phage, produces phagemid particles in which a small proportion of these display a single copy of the fusion protein.

30 Detailed Description of the Invention:

A. Definitions

"Antibodies" (Abs) and "immunoglobulins" (Igs) are glycoproteins having the same structural

characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

5

"Native antibodies" and "native immunoglobulins" are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin
10 isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V_H) followed by a number of constant domains. Each light chain has a variable domain at one end (V_L) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of
15 the heavy chain. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains. Clothia et al., *J. Mol. Biol.* 186, 651 (1985); Novotny et al., *PNAS USA* 82, 4592 (1985).

The term "variable" refers to the fact that certain portions of the variable domains differ
20 extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not evenly distributed through the variable domains of antibodies. It is concentrated in three segments called "complementarily determining regions" (CDRs) or "hypervariable regions" both in the light chain and the heavy chain variable domains. The more highly conserved portions of
25 variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four FR regions, largely adopting a β -sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the β -sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the
30 antigen binding site of antibodies. Kabat et al., *supra*. The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

Papain digestion of antibodies produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an $F(ab')_2$ fragment that has two antigen combining sites and is still capable of cross linking antigen.

5

"Fv" is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V_H - V_L dimer.

10 Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

15 A "Fab" fragment contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab^l fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab^l -SH is the designation herein for Fab^l in which the cysteine residue(s) of the constant domains bear a free thiol group. $F(ab')_2$
20 antibody fragments originally were produced as pairs of Fab^l fragments which have hinge cysteines between them. Other, chemical couplings of antibody fragments are also known.

The light chains of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa (κ) and lambda (λ), based on the amino acid
25 sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided
30 into subclasses (isotypes), e.g. IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , delta, epsilon, γ , and, μ , respectively. The subunit structures and three-dimensional

configurations of different classes of immunoglobulins are well known.

The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with
5 polypeptopic specificity, as well as antibody fragments (*e.g.*, Fab, F(ab')₂, and Fv), so long as they exhibit the desired biological activity.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, *i.e.*, the individual antibodies comprising
10 the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant
15 on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example,
20 the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., *Nature* 256, 495 (1975), or may be made by recombinant DNA methods, see, *e.g.* U.S. Patent No. 4,816,567.

"Chimeric" antibodies (immunoglobulins) are antibodies wherein a portion of the heavy
25 and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity.
30 U.S. Patent No. 4,816,567.

"Humanized" forms of non-human (*e.g.* murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab¹, F(ab')₂ or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details see: Jones et al., *Nature* 321, 522 (1986); Reichmann et al., *Nature* 332, 323 (1988); and Presta, *Curr. Op. Struct. Biol.* 2, 593 (1992).

20

"Non-immunogenic in a human" means that upon contacting the humanized antibody in a therapeutically effective amount with appropriate tissue of a human, a state of sensitivity or resistance to the humanized antibody is not substantially demonstratable upon administration.

25 As used herein, "vascular endothelial cell growth factor," or "VEGF," refers to a mammalian growth factor as defined in U.S. Patent 5,332,671, including the human amino acid sequence of Fig. 1. The biological activity of native VEGF is shared by any analogue or variant thereof that is capable of promoting selective growth of vascular endothelial cells but not of bovine corneal endothelial cells, lens epithelial cells, adrenal cortex cells, BHK-21 fibroblasts, or
30 keratinocytes, or that possesses an immune epitope that is immunologically cross-reactive with an antibody raised against at least one epitope of the corresponding native VEGF.

"Site-directed mutagenesis" is a technique standard in the art, and is conducted using a synthetic oligonucleotide primer complementary to a single-stranded phage DNA to be mutagenized except for limited mismatching, representing the desired mutation. Briefly, the synthetic oligonucleotide is used as a primer to direct synthesis of a strand complementary to the phage, and the resulting double-stranded DNA is transformed into a phage-supporting host bacterium. Cultures of the transformed bacteria are plated in top agar, permitting plaque formation from single cells that harbor the phage. Theoretically, 50% of the new plaques will contain the phage having, as a single strand, the mutated form; 50% will have the original sequence. The plaques are hybridized with kinased synthetic primer at a temperature that permits hybridization of an exact match, but at which the mismatches with the original strand are sufficient to prevent hybridization. Plaques that hybridize with the probe are then selected and cultured, and the DNA is recovered.

"Expression system" refers to DNA sequences containing a desired coding sequence and control sequences in operable linkage, so that hosts transformed with these sequences are capable of producing the encoded proteins. To effect transformation, the expression system may be included on a vector; however, the relevant DNA may then also be integrated into the host chromosome.

As used herein, "cell," "cell line," and "cell culture" are used interchangeably and all such designations include progeny. Thus, "transformants" or "transformed cells" includes the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

"Plasmids" are designated by a lower case p preceded and/or followed by capital letters and/or numbers. The starting plasmids herein are commercially available, are publicly available on an unrestricted basis, or can be constructed from such available plasmids in accord with published procedures. In addition, other equivalent plasmids are known in the art and will be apparent to the ordinary artisan.

"Affinity binding" refers to the strength of the sum total of noncovalent interactions between a single antigen-binding site on an antibody and a single epitope. Low-affinity antibodies bind antigen weakly and tend to dissociate readily, whereas high-affinity antibodies bind antigen more tightly and remain bound longer.

5

"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, *Proc. Natl. Acad. Sci. USA* 69, 2110 (1972) and Mandel et al., *J. Mol. Biol.* 53, 154 (1970), is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, *Virology* 52, 456 (1978) is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Pat. No. 4,399,216 issued August 16, 15 1983. Transformations into yeast are typically carried out according to the method of Van Solingen et al., *J. Bact.* 130, 946 (1977) and Hsiao et al., *Proc. Natl. Acad. Sci. USA* 76, 3829 (1979). However, other methods for introducing DNA into cells such as by nuclear injection, electroporation or by protoplast fusion may also be used.

20 "Recovery" or "isolation" of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For 25 example, see Lawn et al., *Nucleic Acids Res.* 9, 6103 (1981) and Goeddel et al., *Nucleic Acids Res.* 8, 4057 (1980).

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments. Unless otherwise provided, ligation may be accomplished 30 using known buffers and conditions with 10 units of T4 DNA ligase ("ligase") per 0.5 mg of approximately equimolar amounts of the DNA fragments to be ligated.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences.

- 5 Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

- Nucleic acid is "operably linked" or "operatively linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or a secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" or "operatively linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase.
- 10
- 15 However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

- As used herein, "representatively numbered" refers to a position number of a residue in a particular sequence and corresponding position numbers in different sequences. Corresponding position numbers are those positions within sequences, generally human antibody framework sequences, which are functionally equivalent to the representatively numbered position when used in the construction of a humanized antibody.
- 20

- 25 Ordinarily, the terms "amino acid" and "amino acids" refer to all naturally occurring L- α -amino acids. In some embodiments, however, D-amino acids may be present in the polypeptides or peptides of the present invention in order to facilitate conformational restriction. The amino acids are identified by either the single-letter or three-letter designations:

	Asp	D	aspartic acid	Ile	I	isoleucine
	Thr	T	threonine	Leu	L	leucine
	Ser	S	serine	Tyr	Y	tyrosine
	Glu	E	glutamic acid	Phe	F	phenylalanine
5	Pro	P	proline	His	H	histidine
	Gly	G	glycine	Lys	K	lysine
	Ala	A	alanine	Arg	R	arginine
	Cys	C	cysteine	Trp	W	tryptophan
	Val	V	valine	Gln	Q	glutamine
10	Met	M	methionine	Asn	N	asparagine

The term "amino acid sequence variant" refers to molecules with some differences in their amino acid sequences as compared to a native amino acid sequence.

- 15 Substitutional variants are those that have at least one amino acid residue in a native sequence removed and a different amino acid inserted in its place at the same position. The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule.

20

- Hybridization is preferably performed under "stringent conditions" which means (1) employing low ionic strength and high temperature for washing, for example, 0.015 sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C, or (2) employing during hybridization a denaturing agent, such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 nM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C. Another example is use of 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6/8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 25 42°C, with washes at 42°C in 0.2 x SSC and 0.1% SDS. Yet another example is hybridization using a buffer of 10% dextran sulfate, 2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC 30

containing EDTA at 55°C. When a nucleic acid sequence of a nucleic acid molecule is provided, other nucleic acid molecules hybridizing thereto under the conditions described above are considered within the scope of the sequence.

- 5 Where amino acid sequences are described it is understood that these sequences can be reproduced by reconstructing the amino acid sequence synthetically or by mutation. Alternatively, it is understood that recombinant techniques can be used such that the DNA encoding the amino acid sequences is recovered. The DNA is recovered by forming a library from the DNA encoding the desired amino acid sequences. Probes are then generated based
10 on the amino acid sequences. DNA hybridizing to the probes is then isolated and analyzed to determine whether the product encoded by the DNA is the desired product. Generally, cells are transformed with the DNA (or RNA) and expression studies are performed.

B. General Methodology for Humanizing Antibodies

- 15 The methods described herein can be used to humanize any antibody. Similarly, it is understood that the humanized antibody specifically described herein, humanized anti-VEGF, can be reproduced by the methods described herein or by traditional DNA recombinant techniques. Specifically, since the critical framework residue mutations are described herein, the humanized antibody can be reproduced to have the same mutations without being
20 reproduced using the monovalent phage display system. Rather, the DNA encoding the described amino acid sequences can be synthesized or reproduced by traditional DNA recombinant techniques. The DNA product can then be expressed, identified and recovered. Alternatively, site-directed mutagenesis can be performed on the antibody by methods known in the art, or the antibody can be synthesized so as to have the mutations described herein.

25

- A particularly preferred method for producing the humanized antibodies described herein involves the following: preparing an antibody phagemid vector for monovalent display of Fab fragments having CDR sequences transplanted by site-directed mutagenesis onto a vector which codes for a human $V_L\kappa I-C\kappa_1$ light chain and human $V_H III-G_H 1\gamma$ heavy chain Fd;
30 constructing the antibody Fab phagemid library by random mutagenesis of a small set of selected critical framework residues; expressing and purifying the humanized Fab fragments; selecting humanized Fab variants; and, determining binding affinities. These steps do not

have to be performed in any particular order. These steps are specifically described below in the "specific example" but are generally performed as follows:

Preparation of antibody phagemid vector for monovalent display of Fab fragments

5 First an antibody to be humanized is selected and the complementary determining regions (CDRs) identified. The CDR sequences of the antibody can be identified according to the sequence definition of Kabat et al., supra. The CDR sequences are transplanted by site-directed mutagenesis onto a vector which codes for a human $V_L\kappa I$ - $C\kappa_1$ light chain and
10 human V_HIII - $C_HI\gamma_1$ heavy chain Fd. The Fab encoding sequence can then be subcloned into a phagemid vector. This construct encodes an initial humanized antibody wherein the C-terminus of the heavy chain is fused precisely to the carboxyl portion of a phage coat protein. Preferably, a phagemid vector is selected which provides expression of both secreted heavy chain or heavy chain-gene III fusions in *supE* suppressor strains of *E. coli*.

15

Construction of the antibody Fab phagemid library

Based on the cumulative results from humanizing a number of non-human antibodies onto a human $V_L\kappa I$ - V_HIII framework, it was considered that framework changes required to optimize antigen binding are limited to some subset of the residues. See, Carter et al., *PNAS*
20 *USA* 89, 4285 (1992); Presta et al., *J. Immunol.* 151, 2623 (1993); Eigenbrot et al., *Proteins* 18, 49-62 (1994); Shalaby et al., *J. Exp. Med.* 175, 217 (1992). Accordingly, a novel group of residues was selected for randomization. Randomizing these identified key framework residues provides the desired library of Fab variants to be displayed on the surface of filamentous phage. Specifically, V_L residues 4 and 71, and V_H residues 24,
25 37,67,69,71,71,75,76,78,93 and 94 have been selected as key framework residues important for antigen binding and targeted for randomization.

Expression and purification of humanized Fab fragments

Various methods are known in the art to express and purify fragments. As described herein,
30 an *E. coli* strain 34B8, a nonsuppressor, was transformed with phagemid pMB419, or variants thereof. Single colonies were grown overnight at 37°C in 5 mL 2YT containing 50 µg/mL carbenicillin. These cultures were diluted into 200 mL AP5 medium, described in Chang et al., *Gene* 55, 189 (1987), containing 20 µg/mL carbenicillin and incubated for 26

hours at 30°C. The cells were pelleted at 4000 x g and frozen at -20°C for at least 2 hours. Cell pellets were then resuspended in 5 mL of 10 mM Tris-HCl (pH 7.6) containing 1 mM EDTA, shaken at 4°C for 90 minutes and centrifuged at 10,000 x g for 15 minutes. The supernatant was applied to a 1 mL streptococcal protein G-SEPHAROSE column (a column
5 produced by Pharmacia) and washed with 10 mL of 10 mM MES (pH 5.5). The bound Fab fragment was eluted with 2.5 mL 100 mM acetic acid and immediately neutralized with 0.75 mL 1M TrisHCl, pH 8.0. Fab preparations were buffer-exchanged into PBS and concentrated using CENTRICON-30 concentrators (produced by Amicon). Typical yields of Fab were approximately 1 mg/L culture, post-protein G purification. Purified Fab samples
10 were characterized by electrospray mass spectrometry, and concentrations were determined by amino acid analysis.

Selection of humanized Fab variants

Purified labeled antigen is coated onto a microtiter plate. The coating solution is discarded,
15 the wells blocked, and phagemid stock is added. After a period, the wells are washed and the bound phage eluted and titered. The remaining phage eluted from the VEGF-coated well are propagated for use in the next selection cycle. This process can be repeated several times to obtain the desired number of clones. For example, a few dozen individual clones can be selected and sequenced.

20

Determination of VEGF binding affinities

Association and dissociation rate constants for binding of the humanized variants to VEGF are measured. Binding profiles are analyzed and those variants showing the highest affinities are selected.

25

Administration of the humanized anti-VEGF

Administration of the humanized anti-VEGF can be extrapolated from the data presented on the murine anti-VEGF described in Kim et al., *Growth Factors* 7, 53 (1992); Kim et al., *Nature* 362, 841 (1993). In particular, Kim et al. demonstrates that as little as 10 µg twice
30 weekly of the VEGF antibody resulted in significant inhibition of tumor growth. Maximal effects were achieved with antibody doses of 50-100 µg.

The following example is intended merely to illustrate the best mode now known for practicing the invention but the invention is not to be considered as limited to the details of this example.

5

Specific Example I

Construction of the phagemid vector and the initial humanized anti-VEGF

The murine anti-VEGF mAb A4.6.1 has been previously described by Kim et al, *Growth Factors*, 7, 53 (1992); Kim et al., *Nature*, 362, 841 (1993). The first Fab variant of humanized A4.6.1, hu2.0, was constructed by site-directed mutagenesis using a deoxyuridine-containing template of plasmid pAK2 which codes for a human V_LκI-Cκ₁ light chain and human V_HIII-C_HIγ₁ heavy chain Fd fragment. Carter et al., *PNAS USA* 89, 4285 (1992). The transplanted A4.6.1 CDR sequences were chosen according to the sequence definition of Kabat et al., Sequences of Proteins of Immunological Interest (5th), Public Health Service, National Institutes of Health, Bethesda, MD. (1991), except for CDR-H1 which we extended to encompass both sequence and structural definitions, viz V_H residues 26-35, Chothia et al., *J. Mol. Biol.* 196, 901 (1987). The Fab encoding sequence was subcloned into the phagemid vector phGHang3. Bass and Wells, *Proteins*, 8, 309 (1990); Lowman et al., *Biochem.* 30, 10832 (1991). This construct, pMB4-19, encodes the initial humanized A4.6.1 Fab, hu2.0, with the C-terminus of the heavy chain fused precisely to the carboxyl portion of the M13 gene III coat protein. pMB4-19 is similar in construction to pDH188, a previously described plasmid for monovalent display of Fab fragments. Garrard et al., *Biotechn.* 9: 1373-1377 (1991). Notable differences between pMB4-19 and pDH188 include a shorter M13 gene III segment (codons 249-406) and use of an amber stop codon immediately following the antibody heavy chain Fd fragment. This permits expression of both secreted heavy chain or heavy chain-gene III fusions in *supE* suppressor strains of *E. coli*.

The initial humanized A4.6.1 Fab fragment (hu2.0) in which the CDRs from A4.6.1 were grafted onto a human V_LκI-V_HIII framework is shown in Figure 1. The V_L domain of hu2.0 is set forth in SEQ ID NO: 7 and the V_H domain of hu2.0 is set forth in SEQ ID NO: 10.

All residues other than the grafted CDRs were maintained as the human sequence. Binding

of this initial humanized antibody to VEGF was so weak as to be undetectable. Based on the relative affinity of other weakly-binding humanized A4.6.1 variants (data not shown), the K_D for binding of hu2.0 was estimated at $>7 \mu\text{M}$. This contrasts with an affinity of 1.6 nM for a chimeric Fab construct consisting of the intact V_L and V_H domains from murine A4.6.1 and human constant domains. Thus, binding of hu2.0 to VEGF was at least 4000-fold reduced relative to the chimera.

Design of the anti-VEGF Fab phagemid library

The group of framework changes required to optimize antigen binding when using human $V_L\kappa\text{I}-V_H\text{III}$ framework were selected as shown in Table 1 and Figure 2. The humanized A4.6.1 phagemid library was constructed by site-directed mutagenesis according to the method of Kunkel et al., *Methods Enzymol.* 204, 125 (1991). A derivative of pMB4-19 containing TAA stop triplets at V_H codons 24, 37, 67 and 93 was prepared for use as the mutagenesis template (all sequence numbering according to Kabat et al., supra. This modification was to prevent subsequent background contamination by wild type sequences. The codons targeted for randomization were 4 and 71 (light chain) and 24, 37, 67, 69, 71, 73, 75, 76, 78, 93 and 94 (heavy chain).

Table 1: Key framework residues important for antigen binding and targeted for randomization

	Framework residue	Human V κ _L I, V _H III consensus residue	Murine A4.6.1 residue	Randomization ^a
5	V _L : 4	Met	Met	Met, Leu
	71	Phe	Tyr	Phe, Tyr
10	V _H : 24	Ala	Ala	Ala, Val, Thr
	37	Val	Val	Val, Ile
	67	Phe	Phe	Phe, Val, Thr, Leu, Ile, Ala
	69	Ile	Phe	Ile, Phe
15	71	Arg	Leu	Arg ^b , Leu ^b
	73	Asp	Thr	Asp ^b , Thr ^b
	75	Lys	Ala	Lys ^b , Ala ^b
	76	Asn	Ser	Asn ^b , Ser ^b
	78	Leu	Ala	Leu, Ala, Val,
20	Phe			
	93	Ala	Ala	Ala, Val, Leu, Thr
	Ser,			
	94	Arg	Lys	Arg, Lys

25 ^a Amino acid diversity in phagemid library

^b V_H 71, 73, 75, 76 randomized to yield the all-murine (L71/T73/A75/S76) or all-human (R71/D73/K75/N76) V_HIII tetrad

A concern in designing the humanized A4.6.1 phagemid library was that residues targeted for randomization were widely distributed across the V_L and V_H sequences. Limitations in the length of synthetic oligonucleotides requires that simultaneous randomization of each of these framework positions can only be achieved through the use of multiple oligonucleotides. However, as the total number of oligonucleotides increases, the efficiency of mutagenesis decreases (*i.e.* the proportion of mutants obtained which incorporate sequence derived from all of the mutagenic oligonucleotides). To circumvent this problem, two features were incorporated into the library construction. The first was to prepare four different mutagenesis templates coding for each of the possible V_L framework combinations. This was simple to do given the limited diversity of the light chain framework (only 4 different sequences), but was beneficial in that it eliminated the need for two oligonucleotides from the mutagenesis strategy. Secondly, two 126 base oligonucleotides were preassembled from smaller synthetic fragments. This made possible randomization of V_H codons 67, 69, 71, 73,

75, 76, 93 and 94 with a single long oligonucleotide, rather than two smaller ones. The final randomization mutagenesis strategy therefore employed only two oligonucleotides simultaneously onto four different templates.

- 5 More specifically, in order to randomize heavy chain codons 67, 69, 71, 73, 75, 76, 78, 93 and 94 with a single mutagenic oligonucleotide, two 126-mer oligonucleotides were first preassembled from 60 and 66-mer fragments by template-assisted enzymatic ligation. Specifically, 1.5 nmol of 5' phosphorylated oligonucleotide GAT TTC AAA CGT CGT NYT ACT WTT TCT AGA GAC AAC TCC AAA AAC ACA BYT TAC CTG CAG ATG AAC
- 10 (SEQ ID NO: 12) or GAT TTC AAA CGT CGT NYT ACT WTT TCT TTA GAC ACC TCC GCA AGC ACA BYT TAC CTG CAG ATG AAC (SEQ ID NO: 1) were combined with 1.5 nmol of AGC CTG CGC GCT GAG GAC ACT GCC GTC TAT TAC TGT DYA ARG TAC CCC CAC TAT TAT GGG (SEQ ID NO: 2). The randomized codons are underlined and N represents A/G/T/C; W represents A/T; B represents G/T/C; D represents
- 15 G/A/T; R represents A/G; and Y represents C/T ("/" represents "or"). Then, 1.5 nmol of template oligonucleotide CTC AGC GCG CAG GCT GTT CAT CTG CAG GTA (SEQ ID NO: 3), with complementary sequence to the 5' ends of SEQ ID NOS: 12 and 1 and the 3' end of SEQ ID NO: 3 was added to hybridize to each end of the ligation junction. To this mixture, *Taq* ligase (thermostable ligase from New England Biolabs) and buffer were added,
- 20 and the reaction mixture was subjected to 40 rounds of thermal cycling, (95°C for 1.25 minutes and 50°C for 5 minutes) so as to cycle the template oligonucleotide between ligated and unligated junctions. The product 126-mer oligonucleotides were purified on a 6% urea/TBE polyacrylamide gel and extracted from the polyacrylamide in buffer. The two 126-mer products were combined in equal ratio, ethanol precipitated and finally solubilized
- 25 in 10 mM Tris-HCl, 1 mM EDTA. The mixed 126-mer oligonucleotide product was labeled 504-01.

- Randomization of select framework codons (V_L 4, 71; V_H 24, 37, 67, 69, 71, 73, 75, 76, 93, 94) was thus effected in two steps. First, V_L randomization was achieved by preparing three
- 30 additional derivatives of the modified pMB4-19 template. Framework codons 4 and 71 in the light chain were replaced individually or pairwise using the two mutagenic oligonucleotides GCT GAT ATC CAG TTG ACC CAG TCC CCG (SEQ ID NO: 13) and

TCT GGG ACG GAT TAC ACT CTG ACC ATC (SEQ ID NO: 4). Deoxyuridine containing template was prepared from each of these new derivatives. Together with the original template, these four constructs coded for each of the four possible light chain framework sequence combinations (see Table 1).

5

Oligonucleotides 504-01, the mixture of two 126-mer oligonucleotides, and CGT TTG TCC TGT GCA RYT TCT GGC TAT ACC TTC ACC AAC TAT GGT ATG AAC TGG RTC CGT CAG GCC CCG GGT AAG (SEQ ID NO: 5) were used to randomize heavy chain framework codons using each of the four templates just described. The four libraries were
10 electroporated into *E. coli* XL-1 BLUE CELLS (marker cells produced by Stratagene) and combined. The total number of independent transformants was estimated at $>1.2 \times 10^8$, approximately 1,500-fold greater than the maximum number of DNA sequences in the library.

From this strategy, each of residues 4 and 71 in the light chain and 24, 37, 67, 78 and 93
15 from the heavy chain were partially randomized to allow the selection of either the murine A4.6.1, human $V_L\kappa I$ - V_H III sequence, or sequences commonly found in other human and murine frameworks (Table I). Note that randomization of these residues was not confined to a choice between the human $V_L\kappa I$ - V_H III consensus or A4.6.1 framework sequences. Rather, inclusion of additional amino acids commonly found in other human and murine
20 framework sequences allows for the possibility that additional diversity may lead to the selection of tighter binding variants.

Some of the heavy chain framework residues were randomized in a binary fashion according to the human V_H III and murine A4.6.1 framework sequences. Residues V_H 71, 73, 75 and
25 76 are positioned in a hairpin loop adjacent to the antigen binding site. The side chains of V_H 71 and 73 are largely buried in canonical antibody structures and their potential role in shaping the conformation of CDR-H2 and CDR-H3 is well known. Kettleborough et al., *Protein Eng.* 4, 773 (1991); Carter et al., *PNAS USA* 89, 4285 (1992); Shalaby et al., *J. Exp. Med.* 175, 217 (1992). On the other hand, although the side chains of V_H 75 and 76
30 are solvent exposed (Figure 2), it has nevertheless been observed that these two residues can also influence antigen binding (Eigenbrot, *Proteins* 18, 49 [1994]), presumably due to direct antigen contact in some antibody-antigen complexes. Because of their proximity in sequence

and possible interdependence, V_H 71, 73, 75 and 76 were randomized en bloc such that only two possible combinations of this tetrad could be selected; either all human V_HIII or all murine A4.6.1 sequence. Finally, V_H residues 69 and 94 were randomized, but only to represent the V_HIII and A4.6.1 sequences. The V_H 69 and 94 were not replaced in previous antibody humanizations, but because they differ between the V_HIII consensus and A4.6.1 sequences (Figure 1) and have been noted as potentially important for proper CDR conformation (Foote et al., *J. Mol. Biol.* 224, 487 [1992]), they were included in this randomization strategy.

10 Humanized A4.6.1 Fab library displayed on the surface of phagemid

A variety of systems have been developed for the functional display of antibody fragments on the surface of filamentous phage. Winter et al., *Ann. Rev. Immunol.* 12, 433 (1994). These include the display of Fab or single chain Fv (scFv) fragments as fusions to either the gene III or gene VIII coat proteins of M13 bacteriophage. The system selected herein is similar to that described by Garrard et al., *Biotechn.* 9, 1373 (1991) in which a Fab fragment is monovalently displayed as a gene III fusion (Figure 3). This system has two notable features. In particular, unlike scFvs, Fab fragments have no tendency to form dimeric species, the presence of which can prevent selection of the tightest binders due to avidity effects. Additionally, the monovalency of the displayed protein eliminates a second potential source of avidity effects that would otherwise result from the presence of multiple copies of a protein on each phagemid particle. Bass and Wells, *Proteins* 8, 309 (1990); Lowman et al., *Biochemistry* 30, 10832 (1991).

Phagemid particles displaying the humanized A4.6.1 Fab fragments were propagated in *E. coli* XL-1 Blue cells. Briefly, cells harboring the randomized pMB4-19 construct were grown overnight at 37°C in 25 mL 2YT medium containing 50 µg/mL carbenicillin and approximately 10¹⁰ M13KO7 helper phage (Viera and Messing, *Methods Enzymol.* 153, 3 [1987]). Phagemid stocks were purified from culture supernatants by precipitation with a saline polyethylene glycol solution, and resuspended in 100 µL PBS (approximately 10¹⁴ phagemid/mL).

Selection of humanized A4.6.1 Fab variants

Purified VEGF₁₂₁ (100 µL at 10 µg/mL in PBS) was coated onto a microtiter plate well overnight at 4°C. The coating solution was discarded and this well and an uncoated well were blocked with 6% skim milk for 1 hour and washed with PBS containing 0.05% 5 TWEEN-20 (detergent). Then, 10 µL of phagemid stock, diluted to 100 µL with 20 mM Tris (pH 7.5) containing 0.1% BSA and 0.05% TWEEN-20, was added to each well. After 2 hours, the wells were washed and the bound phage eluted with 100 µL of 0.1 M glycine (pH 2.0), and neutralized with 25 µL of 1M Tris pH 8.0. An aliquot of this was used to titer the number of phage eluted. The remaining phage eluted from the VEGF-coated well were 10 propagated for use in the next selection cycle. A total of 8 rounds of selection was performed after which time 20 individual clones were selected and sequenced (Sanger et al., *PNAS USA* 74, 5463 [1977]).

Variants from the humanized A4.6.1 Fab phagemid library were thusly selected based on 15 binding to VEGF. Enrichment of functional phagemid, as measured by comparing titers for phage eluted from a VEGF-coated versus uncoated microtiter plate well, increased up to the seventh round of affinity panning. After one additional round of sorting, 20 clones were sequenced to identify preferred framework residues selected at each position randomized. These results, summarized in Table 2, revealed strong consensus amongst the clones selected. 20 Ten out of the twenty clones had the identical DNA sequence, designated hu2.10. Of the thirteen framework positions randomized, eight substitutions were selected in hu2.10 (V_L 71; V_H 37, 71, 73, 75, 76, 78 and 94). Interestingly, residues V_H 37 (Ile) and 78 (Val) were selected neither as the human V_HIII or murine A4.6.1 sequence. This result suggests that some framework positions may benefit from extending the diversity beyond the target human 25 and parent murine framework sequences.

Table 2: Sequences selected from the humanized A4.6.1 phagemid Fab library

Variant	Residue substitutions													
	V _L	V _H												
	4	71	24	37	67	69	71	73	75	76	78	93	94	
5 murine A4.6.1	M	Y	A	V	F	F	L	T	A	S	A	A	K	
10 hu2.0 (CDR-graft)	M	F	A	V	F	<u>I</u>	<u>R</u>	<u>N</u>	<u>K</u>	<u>N</u>	<u>L</u>	A	<u>R</u>	
Phage-selected clones:														
hu2.1 (2)	-	Y	-	I	-	-	-	-	-	-	V	-	K	
hu2.2 (2)	L	Y	-	I	-	-	-	-	-	-	V	-	K	
15 hu2.6 (1)	L	-	-	I	T	-	L	T	A	S	V	-	K	
hu2.7 (1)	L	-	-	I	T	-	-	-	-	-	V	-	K	
hu2.10 (10)	-	Y	-	I	-	-	L	T	A	S	V	-	K	

20 Differences between hu2.0 and murine A4.6.1 antibodies are underlined. The number of identical clones identified for each phage-selected sequence is indicated in parentheses. Dashes in the sequences of phage-selected clones indicate selection of the human V_LκI-V_HIII framework sequence (i.e. as in hu2.0).

25 There were four other unique amino acid sequences among the remaining ten clones analyzed: hu2.1, hu2.2, hu2.6 and hu2.7. All of these clones, in addition to hu2.10, contained identical framework substitutions at positions V_H 37 (Ile), 78 (Val) and 94 (Lys), but retained the human V_HIII consensus sequence at positions 24 and 93. Four clones had lost the light chain coding sequence and did not bind VEGF when tested in a phage ELISA assay (Cunningham et al., *EMBO J.* 13, 2508 [1994]). We have occasionally noted the loss

30 of heavy or light chain sequence with other Fab phagemid libraries (unpublished data), and these clones are presumably selected for on the basis of enhanced expression. Such artifacts can often be minimized by reducing the number of sorting cycles or by propagating libraries on solid media.

Determination of VEGF binding affinities

Association (k_{on}) and dissociation (k_{off}) rate constants for binding of humanized A4.6.1 Fab variants to VEGF₁₂₁ were measured by surface plasmon resonance (Karlsson et al, *J. Immun. Methods* 145, 229 [1991]) on a Pharmacia BIAcore instrument. VEGF₁₂₁ was covalently immobilized on the biosensor chip via primary amino groups. Binding of humanized A4.6.1 Fab variants was measured by flowing solutions of Fab in PBS/0.05% TWEEN-20 (detergent) over the chip at a flow rate of 20 μ L/min. Following each binding measurement, residual Fab was stripped from the immobilized ligand by washing with 5 μ L of 50 mM aqueous HCl at 3 μ L/min. Binding profiles were analyzed by nonlinear regression using a simple monovalent binding model (BIAevaluation software v2.0; Pharmacia).

Phage-selected variants hu2.1, hu2.2, hu2.6, hu2.7 and hu2.10 were expressed in *E. coli* using shake flasks and Fab fragments were purified from periplasmic extracts by protein G affinity chromatography. Recovered yields of Fab for these five clones ranged from 0.2 (hu2.6) to 1.7 mg/L (hu2.1). The affinity of each of these variants for antigen (VEGF) measured by surface plasmon resonance on a BIAcore instrument as shown in Table 3.

Table 3: VEGF binding affinity of humanized A4.6.1 Fab variants.

Variant	k_{on}	k_{off}	K_D	$\frac{K_D(A4.6.1)}{K_D(mut)}$	
	$M^{-1}s^{-1}/10^4$	10^4s^{-1}	nM		
A4.6.1 chimera	5.4	0.85	1.6		
hu2.0	ND	ND		>7000**	>4000
Phage selected clones:					
hu2.1	0.70	18	260	170	
hu2.2	0.47	16	340	210	
hu2.6	0.67	4.5	67	40	
hu2.7	0.67	24	360	230	
hu2.10	0.63	3.5	55	35	
*hu2.10V	2.0	1.8	9.3	5.8	

*hu2.10V = hu2.10 with mutation V_L Leu46 -> Val; Estimated errors in the Biacore binding measurements are +/- 25%; **Too weak to measure, estimate of lower bound

Analysis of this binding data revealed that the consensus clone hu2.10 possessed the highest affinity for VEGF out of the five variants tested. Thus our Fab phagemid library was selectively enriched for the tightest binding clone. The calculated K_D for hu2.10 was 55 nM, at least 125-fold tighter than for hu2.0- which contains no framework changes ($K_D > 7 \mu\text{M}$).
5 The other four selected variants all exhibited weaker binding to VEGF, ranging down to a K_D of 360 nM for the weakest (hu2.7). Interestingly, the K_D for hu2.6, 67 nM, was only marginally weaker than that of hu2.10 and yet only one copy of this clone was found among 20 clones sequenced. This may have due to a lower level of expression and display, as was the case when expressing the soluble Fab of this variant. However, despite the lower
10 expression rate, this variant is useful as a humanized antibody.

Additional improvement of humanized variant hu2.10

Despite the large improvement in antigen affinity over the initial humanized variant, binding of hu2.10 to VEGF was still 35-fold weaker than a chimeric Fab fragment containing the
15 murine A4.6.1 V_L and V_H domains. This considerable difference suggested that further optimization of the humanized framework might be possible through additional mutations. Of the vernier residues identified by Foote et al., *J. Mol. Biol.* 196, 901 (1992), only residues V_L 46, V_H 2 and V_H 48 differed in the A4.6.1 versus human $V_{\kappa\text{I}}\text{-}V_{\text{HIII}}$ framework (Figure 1) but were not randomized in our phagemid library. A molecular model of the humanized
20 A4.6.1 Fv fragment showed that V_L 46 sits at the V_L - V_H interface and could influence the conformation of CDRH3. Furthermore, this amino acid is almost always leucine in most $V_L\kappa$ frameworks (Kabat et al., supra.), but is valine in A4.6.1. Accordingly, a Leu \rightarrow Val substitution was made at this position in the background of hu2.10. Analysis of binding kinetics for this new variant, hu2.10V, indicated a further 6-fold improvement in the K_D for
25 VEGF binding. The K_D for hu2.10V (9.3 nM) was thus within 6-fold that of the chimera. In contrast to V_L 46, no improvement in the binding affinity of hu2.10 was observed for replacement of either V_H 2 or V_H 48 with the corresponding residue from murine A4.6.1.

Interestingly, part of the improvement prior to the last change in affinity was due to an
30 increase in the association rate constant (k_{on}), suggesting that V_L 46 may play a role in preorganizing the antibody structure into a conformation more suitable for antigen binding. Other mutations which affected antigen affinity were primarily due to changes in the

dissociation rate constant (k_{off}) for binding. Comparison of hu2.1 and hu2.10 reveals a 5-fold improvement in affinity for substitution of V_H residues 71, 73, 75, 76 with the A4.6.1 sequence. Conversion of V_L -71 to the A4.6.1 sequence (Phe \rightarrow Tyr) had negligible effect on binding (hu2.2 vs hu2.7), while variants with leucine at V_L 4 bound marginally worse (5 (<2-fold) than those with methionine, the naturally occurring residue in both the A4.6.1 and human V_{KL} I frameworks (hu2.2 vs hu2.1). Comparison of other humanized A4.6.1 variants not shown here revealed that the V_H 94 Arg \rightarrow Lys change resulted in a 5-fold improvement in K_D , either due to direct antigen contact by this residue, or to a structural role in maintaining the proper conformation of CDR-H3. Variant hu2.6 has three sequence differences relative to the consensus clone hu2.10, but nevertheless has a similar K_D , thereby suggesting that these three substitutions have little effect on antigen binding. The negligible effect of conservative changes at V_L 4 and 71 concurs with binding data for other variants, yet the change at V_H 67 (Phe \rightarrow Thr) had little effect on binding.

15 Concluding Remarks

The foregoing description details specific methods which can be employed to practice the present invention. Having detailed such specific methods, those skilled in the art will well enough know how to devise alternative reliable methods at arriving at the same information by using the fruits of the present invention. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope thereof; rather, the ambit of the present invention is to be determined only by the lawful construction of the appended claims. All documents cited herein are hereby expressly incorporated by reference.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Genentech, Inc.
- 5 (ii) TITLE OF INVENTION: HUMANIZED ANTIBODIES AND METHODS FOR FORMING HUMANIZED ANTIBODIES
- (iii) NUMBER OF SEQUENCES: 14
- 10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Flehr, Hohbach, Test, Albritton & Herbert
(B) STREET: Four Embarcadero Center, Suite 3400
(C) CITY: San Francisco
(D) STATE: California
15 (E) COUNTRY: United States
(F) ZIP: 94111
- (v) COMPUTER READABLE FORM:
20 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
25 (A) APPLICATION NUMBER: PCT HEREWITH
(B) FILING DATE: 02-APR-1998
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
30 (A) APPLICATION NUMBER: 08/833,504
(B) FILING DATE: 07-APR-1997
- (viii) ATTORNEY/AGENT INFORMATION:
35 (A) NAME: Dreger, Walter H.
(B) REGISTRATION NUMBER: 24,190
(C) REFERENCE/DOCKET NUMBER: A-64254
- (ix) TELECOMMUNICATION INFORMATION:
40 (A) TELEPHONE: (415) 781-1989
(B) TELEFAX: (415) 398-3249

(2) INFORMATION FOR SEQ ID NO:1:

- 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
50 (D) TOPOLOGY: unknown
- (ii) MOLECULE TYPE: DNA (genomic)
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- 55 GATTTCAAAC GTCGTNYTAC TWTTTCTTTA GACACCTCCG CAAGCACABY TTACCTGCAG 60
ATGAAC 66

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 60 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AGCCTGCGCG CTGAGGACAC TGCCGTCTAT TACTGTDYAA RGTACCCCCA CTATTATGGG 60

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CTCAGCGCGC AGGCTGTTCA TCTGCAGGTA 30

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TCTGGGACGG ATTACACTCT GACCATC 27

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: unknown
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CGTTTGTCTT GTGCARYTTC TGGCTATAACC TTCACCAACT ATGGTATGAA CTGGRTCCGT 60

CAGGCCCCGG GTAAG 75

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly
 1 5 10 15
 Asp Arg Val Ile Ile Ser Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Val Leu Ile
 35 40 45
 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
 65 70 75 80
 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

35 (2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: unknown
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30
 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45
 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80
 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
 85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

5 (2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 107 amino acids
(B) TYPE: amino acid
10 (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
20 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
25 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
30 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Thr Val Pro Trp
85 90 95
35 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

40 (2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
(B) TYPE: amino acid
45 (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Glu Ile Gln Leu Val Gln Ser Gly Pro Glu Leu Lys Gln Pro Gly Glu
1 5 10 15
55 Thr Val Arg Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met
35 40 45
60 Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe
50 55 60
Lys Arg Arg Phe Thr Phe Ser Leu Glu Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Leu	Gln	Ile	Ser	Asn	Leu	Lys	Asn	Asp	Asp	Thr	Ala	Thr	Tyr	Phe	Cys
				85					90					95	
Ala	Lys	Tyr	Pro	His	Tyr	Tyr	Gly	Ser	Ser	His	Trp	Tyr	Phe	Asp	Val
			100					105					110		
Trp	Gly	Ala	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser					
		115					120								

10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

	Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly
25	1			5					10						15	
	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asn	Tyr
				20					25					30		
30	Gly	Met	Asn	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val
			35				40						45			
	Gly	Trp	Ile	Asn	Thr	Tyr	Thr	Gly	Glu	Pro	Thr	Tyr	Ala	Ala	Asp	Phe
	50					55						60				
35	Lys	Arg	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr
	65					70					75					80
	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys
40				85					90						95	
	Ala	Arg	Tyr	Pro	His	Tyr	Tyr	Gly	Ser	Ser	His	Trp	Tyr	Phe	Asp	Val
				100					105					110		
45	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser					
			115					120								

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 123 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

60 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30

	Gly	Met	Asn	Trp	Ile	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	
		35						40					45				
5	Gly	Trp	Ile	Asn	Thr	Tyr	Thr	Gly	Glu	Pro	Thr	Tyr	Ala	Ala	Asp	Phe	
		50					55					60					
	Lys	Arg	Arg	Phe	Thr	Ile	Ser	Leu	Asp	Thr	Ser	Ala	Ser	Thr	Val	Tyr	
	65					70					75					80	
10	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	
					85					90					95		
	Ala	Lys	Tyr	Pro	His	Tyr	Tyr	Gly	Ser	Ser	His	Trp	Tyr	Phe	Asp	Val	
				100					105					110			
15	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser						
			115					120									

20 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 66 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: DNA (genomic)

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

35 GATTTCAAAC GTCGTNYTAC TWTTTCTAGA GACAACTCCA AAAACACABY TTACCTGCAG 60
ATGAAC 66

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

45 (ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

50 GCTGATATCC AGTTGACCCA GTCCCCG 27

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 6072 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown

60 (ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- ```
(A) NAME/KEY: misc_feature
(B) LOCATION: 459..460
```

(D) OTHER INFORMATION: /note= "Light chain begins at base no. 459."

(ix) FEATURE:

5 (A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1101..1102  
 (D) OTHER INFORMATION: /note= "Light chain terminates at base no. 1101."

10 (ix) FEATURE:

(A) NAME/KEY: misc\_feature  
 (B) LOCATION: 1254..1255  
 (D) OTHER INFORMATION: /note= "Heavy chain begins at base no. 1254."

15 (ix) FEATURE:

(A) NAME/KEY: misc\_feature  
 (B) LOCATION: 2424..2425  
 (D) OTHER INFORMATION: /note= "Heavy chain terminates at base no. 2424."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

|    |                                                                   |      |
|----|-------------------------------------------------------------------|------|
| 25 | GAATTCAACT TCTCCATACT TTGGATAAGG AAATACAGAC ATGAAAAATC TCATTGCTGA | 60   |
|    | GTTGTTATTT AAGCTTTGGA GATTATCGTC ACTGCAATGC TTCGCAATAT GGCACAAAAT | 120  |
|    | GACCAACAGC GGTGATTGA TCAGGTAGAG GGGGCGCTGT ACGAGGTAAA GCCCGATGCC  | 180  |
| 30 | AGCATTCCTG ACGACGATAC GGAGCTGCTG CGCGATTACG TAAAGAAGTT ATTGAAGCAT | 240  |
|    | CCTCGTCAGT AAAAAGTTAA TCTTTTCAAC AGCTGTCATA AAGTTGTCAC GGCCGAGACT | 300  |
| 35 | TATAGTCGCT TTGTTTTTAT TTTTAAATGT ATTTGTAAC AGAATTCGAG CTCGGTACCC  | 360  |
|    | GGGGATCCTC TAGAGGTTGA GGTGATTTTA TGAAAAAGAA TATCGCATTT CTTCTTGCAT | 420  |
|    | CTATGTTTCGT TTTTCTATT GCTACAAACG CGTACGCTGA TATCCAGATG ACCCAGTCCC | 480  |
| 40 | CGAGCTCCCT GTCCGCCTCT GTGGGCGATA GGGTCACCAT CACCTGCAGC GCAAGTCAGG | 540  |
|    | ATATTAGCAA CTATTTAAAC TGGTATCAAC AGAAACCAGG AAAAGCTCCG AAAGTACTGA | 600  |
| 45 | TTTACTTCAC CTCCTCTCTC CACTCTGGAG TCCCTTCTCG CTTCTCTGGA TCCGGTTCTG | 660  |
|    | GGACGGATTA CACTCTGACC ATCAGCAGTC TGCAGCCAGA AGACTTCGCA ACTTATTACT | 720  |
|    | GTCAACAGTA TAGCACCGTG CCGTGGACGT TTGGACAGGG TACCAAGGTG GAGATCAAAC | 780  |
| 50 | GAACTGTGGC TGCACCATCT GTCTTCATCT TCCCGCCATC TGATGAGCAG TTGAAATCTG | 840  |
|    | GAACTGCTTC TGTTGTGTGC CTGCTGAATA ACTTCTATCC CAGAGAGGCC AAAGTACAGT | 900  |
| 55 | GGAAGGTGGA TAACGCCCTC CAATCGGGTA ACTCCCAGGA GAGTGTACA GAGCAGGACA  | 960  |
|    | GCAAGGACAG CACCTACAGC CTCAGCAGCA CCCTGACGCT GAGCAAAGCA GACTACGAGA | 1020 |
|    | AACACAAAGT CTACGCCTGC GAAGTCACCC ATCAGGGCCT GAGCTCGCCC GTCACAAAGA | 1080 |
| 60 | GCTTCAACAG GGGAGAGTGT TAAGCTGATC CTCTACGCCG GACGCATCGT GGCCCTAGTA | 1140 |
|    | CGCAACTAGT CGTAAAAAGG GTATCTAGAG GTTGAGGTGA TTTTATGAAA AAGAATATCG | 1200 |
|    | CATTTCTTCT TGCATCTATG TTCGTTTTTT CTATTGCTAC AAACGCGTAC GCTGAGGTTC | 1260 |

AGCTGGTGGA GTCTGGCGGT GGCCTGGTGC AGCCAGGGGG CTCACTCCGT TTGTCCTGTG 1320  
 CAGCTTCTGG CTATACCTTC ACCAACTATG GTATGAACTG GATCCGTCAG GCCCCGGGTA 1380  
 5 AGGGCCTGGA ATGGGTTGGA TGGATTAACA CCTATACCGG TGAACCGACC TATGCTGCGG 1440  
 ATTTCAAACG TCGTTTTACT ATTTCTTTAG ACACCTCCGC AAGCACAGTT TACCTGCAGA 1500  
 10 TGAACAGCCT GCGCGCTGAG GACACTGCCG TCTATTACTG TGCAAAGTAC CCCCCTATT 1560  
 ATGGGAGCAG CCACTGGTAT TTCGACGTCT GGGGTCAAGG AACCTGGTC ACCGTCTCCT 1620  
 CGGCCTCCAC CAAGGGCCCA TCGGTCTTCC CCCTGGCACC CTCCTCCAAG AGCACCTCTG 1680  
 15 GGGGCACAGC GGCCCTGGGC TGCCTGGTCA AGGACTACTT CCCCGAACCG GTGACGGTGT 1740  
 CGTGGAAGTC AGGCGCCCTG ACCAGCGGCG TGCACACCTT CCCGGCTGTC CTACAGTCCT 1800  
 CAGGACTCTA CTCCCTCAGC AGCGTGGTGA CCGTGCCCTC CAGCAGCTTG GGCACCCAGA 1860  
 20 CCTACATCTG CAACGTGAAT CACAAGCCCA GCAACACCAA GGTCGACAAG AAAGTTGAGC 1920  
 CCAAATCTTG TGACAAAAC CACCTCTAGA GTGGCGGTGG CTCTGGTTCC GGTGATTTTG 1980  
 25 ATTATGAAAA GATGGCAAAC GCTAATAAGG GGGCTATGAC CGAAAATGCC GATGAAAACG 2040  
 CGCTACAGTC TGACGCTAAA GGCAAACCTG ATTCTGTCGC TACTGATTAC GGTGCTGCTA 2100  
 TCGATGGTTT CATTGGTGAC GTTCCGGCC TTGCTAATGG TAATGGTGCT ACTGGTGATT 2160  
 30 TTGCTGGCTC TAATTCCCAA ATGGCTCAAG TCGGTGACGG TGATAATTCA CCTTTAATGA 2220  
 ATAATTTCCG TCAATATTTA CCTTCCCTCC CTCAATCGGT TGAATGTCGC CCTTTTGTCT 2280  
 35 TTAGCGCTGG TAAACCATAT GAATTTTCTA TTGATTGTGA CAAAATAAAC TTATTCCGTG 2340  
 GTGTCTTTGC GTTCTTTTA TATGTTGCCA CCTTTATGTA TGTATTTTCT ACGTTTGCTA 2400  
 ACATACTGCG TAATAAGGAG TCTTAATCAT GCCAGTTCTT TTGGCTAGCG CCGCCCTATA 2460  
 40 CCTTGTCTGC CTCCCCGCGT TGCGTCGCGG TGCATGGAGC CGGGCCACCT CGACCTGAAT 2520  
 GGAAGCCGGC GGCACCTCGC TAACGGATTC ACCACTCCAA GAATTGGAGC CAATCAATTC 2580  
 45 TTGCGGAGAA CTGTGAATGC GCAAACCAAC CCTTGGCAGA ACATATCCAT CGCGTCCGCC 2640  
 ATCTCCAGCA GCCGCACGCG GCGCATCTCG GGCAGCGTTG GGTCTGGCC ACGGGTGC GC 2700  
 ATGATCGTGC TCCTGTCGTT GAGGACCCGG CTAGGCTGGC GGGGTTGCCT TACTGGTTAG 2760  
 50 CAGAATGAAT CACCGATACG CGAGCGAACG TGAAGCGACT GCTGCTGCAA AACGTCTGCG 2820  
 ACCTGAGCAA CAACATGAAT GGTCTTCGGT TTCCGTGTTT CGTAAAGTCT GGAAACGCGG 2880  
 55 AAGTCAGCGC CCTGCACCAT TATGTTCCGG ATCTGCATCG CAGGATGCTG CTGGCTACCC 2940  
 TGTGGAACAC CTACATCTGT ATTAACGAAG CGCTGGCATT GACCCTGAGT GATTTTTCTC 3000  
 TGGTCCCGCC GCATCCATAC CGCCAGTTGT TTACCCTCAC AACGTTCCAG TAACCGGGCA 3060  
 60 TGTTTCATCAT CAGTAACCCG TATCGTGAGC ATCCTCTCTC GTTTCATCGG TATCATTACC 3120  
 CCCATGAACA GAAATTCCCC CTTACACGGA GGCATCAAGT GACCAAACAG GAAAAACCG 3180

|    |            |            |             |            |            |            |      |
|----|------------|------------|-------------|------------|------------|------------|------|
|    | CCCTTAACAT | GGCCCGCTTT | ATCAGAAGCC  | AGACATTAAC | GCTTCTGGAG | AAACTCAACG | 3240 |
|    | AGCTGGACGC | GGATGAACAG | GCAGACATCT  | GTGAATCGCT | TCACGACCAC | GCTGATGAGC | 3300 |
| 5  | TTTACCGCAG | GATCCGGA   | TTGTAAACGT  | TAATATTTTG | TTAAAATTCG | CGTTAAATTT | 3360 |
|    | TTGTAAATC  | AGCTCATTTT | TTAACCAATA  | GGCCGAAATC | GGCAAAATCC | CTTATAAATC | 3420 |
| 10 | AAAAGAATAG | ACCGAGATAG | GGTTGAGTGT  | TGTTCCAGTT | TGGAACAAGA | GTCCACTATT | 3480 |
|    | AAAGAACGTG | GACTCCAACG | TCAAAGGGCG  | AAAAACCGTC | TATCAGGGCT | ATGGCCCACT | 3540 |
|    | ACGTGAACCA | TCACCCTAAT | CAAGTTTTTT  | GGGGTCGAGG | TGCCGTAAAG | CACTAAATCG | 3600 |
| 15 | GAACCCTAAA | GGGAGCCCC  | GATTTAGAGC  | TTGACGGGGA | AAGCCGGCGA | ACGTGGCGAG | 3660 |
|    | AAAGGAAGGG | AAGAAAGCGA | AAGGAGCGGG  | CGCTAGGGCG | CTGGCAAGTG | TAGCGGTCAC | 3720 |
| 20 | GCTGCGCGTA | ACCACCACAC | CCGCCGCGCT  | TAATGCGCCG | CTACAGGGCG | CGTCCGGATC | 3780 |
|    | CTGCCTCGCG | CGTTTCGGTG | ATGACGGTGA  | AAACCTCTGA | CACATGCAGC | TCCCGGAGAC | 3840 |
|    | GGTCACAGCT | TGTCTGTAAG | CGGATGCCGG  | GAGCAGACAA | GCCCGTCAGG | GCGCGTCAGC | 3900 |
| 25 | GGGTGTTGGC | GGGTGTCGGG | GCGCAGCCAT  | GACCCAGTCA | CGTAGCGATA | GCGGAGTGTA | 3960 |
|    | TACTGGCTTA | ACTATGCGGC | ATCAGAGCAG  | ATTGTACTGA | GAGTGCACCA | TATGCGGTGT | 4020 |
| 30 | GAAATACCGC | ACAGATGCGT | AAGGAGAAAA  | TACCGCATCA | GGCGCTCTTC | CGCTTCCTCG | 4080 |
|    | CTCACTGACT | CGCTGCGCTC | GGTCGTTTCGG | CTGCGGCGAG | CGGTATCAGC | TCACTCAAAG | 4140 |
|    | GCGGTAATAC | GGTTATCCAC | AGAATCAGGG  | GATAACGCAG | GAAAGAACAT | GTGAGCAAAA | 4200 |
| 35 | GGCCAGCAAA | AGGCCAGGAA | CCGTAAAAAG  | GCCGCGTTGC | TGGCGTTTTT | CCATAGGCTC | 4260 |
|    | CGCCCCCTG  | ACGAGCATCA | CAAAAATCGA  | CGCTCAAGTC | AGAGGTGGCG | AAACCCGACA | 4320 |
| 40 | GGACTATAAA | GATACCAGGC | GTTTCCCCCT  | GGAAGCTCCC | TCGTGCGCTC | TCCTGTTCCG | 4380 |
|    | ACCCTGCCGC | TTACCGGATA | CCTGTCCGCC  | TTTCTCCCTT | CGGGAAGCGT | GGCGCTTTCT | 4440 |
|    | CATAGCTCAC | GCTGTAGGTA | TCTCAGTTCG  | GTGTAGGTCG | TTGCTCCAA  | GCTGGGCTGT | 4500 |
| 45 | GTGCACGAAC | CCCCCGTTCA | GCCCGACCGC  | TGCGCCTTAT | CCGGTAACTA | TCGTCTTGAG | 4560 |
|    | TCCAACCCGG | TAAGACACGA | CTTATCGCCA  | CTGGCAGCAG | CCACTGGTAA | CAGGATTAGC | 4620 |
| 50 | AGAGCGAGGT | ATGTAGGCGG | TGCTACAGAG  | TTCTTGAAGT | GGTGGCCTAA | CTACGGCTAC | 4680 |
|    | ACTAGAAGGA | CAGTATTTGG | TATCTGCGCT  | CTGCTGAAGC | CAGTTACCTT | CGGAAAAAGA | 4740 |
|    | GTTGGTAGCT | CTTGATCCGG | CAAACAAACC  | ACCGCTGGTA | GCGGTGGTTT | TTTTGTTTGC | 4800 |
| 55 | AAGCAGCAGA | TTACGCGCAG | AAAAAAAGGA  | TCTCAAGAAG | ATCCTTTGAT | CTTTTCTACG | 4860 |
|    | GGGTCTGACG | CTCAGTGGA  | CGAAACTCA   | CGTTAAGGGA | TTTTGGTCAT | GAGATTATCA | 4920 |
| 60 | AAAAGGATCT | TCACCTAGAT | CCTTTTAAAT  | TAAAAATGAA | GTTTTAAATC | AATCTAAAGT | 4980 |
|    | ATATATGAGT | AAACTTGGTC | TGACAGTTAC  | CAATGCTTAA | TCAGTGAGGC | ACCTATCTCA | 5040 |
|    | GCGATCTGTC | TATTTTCGTT | ATCCATAGTT  | GCCTGACTCC | CCGTCGTGTA | GATAACTACG | 5100 |

|    |            |            |             |             |            |             |      |
|----|------------|------------|-------------|-------------|------------|-------------|------|
|    | ATACGGGAGG | GCTTACCATC | TGGCCCCAGT  | GCTGCAATGA  | TACCGCGAGA | CCCACGCTCA  | 5160 |
|    | CCGGCTCCAG | ATTTATCAGC | AATAAACCAG  | CCAGCCGGAA  | GGGCCGAGCG | CAGAAGTGGT  | 5220 |
| 5  | CCTGCAACTT | TATCCGCCTC | CATCCAGTCT  | ATTAATTGTT  | GCCGGAAGC  | TAGAGTAAGT  | 5280 |
|    | AGTTCGCCAG | TTAATAGTTT | GCGCAACGTT  | GTTGCCATTG  | CTGCAGGCAT | CGTGGTGTCA  | 5340 |
|    | CGCTCGTCGT | TTGGTATGGC | TTCATTTCAGC | TCCGGTTCCC  | AACGATCAAG | GCGAGTTACA  | 5400 |
| 10 | TGATCCCCCA | TGTTGTGCAA | AAAAGCGGTT  | AGCTCCTTCG  | GTCCTCCGAT | CGTTGTCAGA  | 5460 |
|    | AGTAAGTTGG | CCGCAGTGTT | ATCACTCATG  | GTTATGGCAG  | CACTGCATAA | TTCTCTTACT  | 5520 |
| 15 | GTCATGCCAT | CCGTAAGATG | CTTTTCTGTG  | ACTGGTGAGT  | ACTCAACCAA | GTCATTCTGA  | 5580 |
|    | GAATAGTGTA | TGCGGCGACC | GAGTTGCTCT  | TGCCCCGGCGT | CAACACGGGA | TAATACGCG   | 5640 |
|    | CCACATAGCA | GAACTTTAAA | AGTGCTCATC  | ATTGGAAAAC  | GTTCTTCGGG | GCGAAAACCTC | 5700 |
| 20 | TCAAGGATCT | TACCGCTGTT | GAGATCCAGT  | TCGATGTAAC  | CCACTCGTGC | ACCCAACCTGA | 5760 |
|    | TCTTCAGCAT | CTTTTACTTT | CACCAGCGTT  | TCTGGGTGAG  | CAAAAACAGG | AAGGCAAAAT  | 5820 |
| 25 | GCCGCAAAAA | AGGGAATAAG | GCGGACACGG  | AAATGTTGAA  | TACTCATACT | CTTCCTTTTT  | 5880 |
|    | CAATATTATT | GAAGCATTTA | TCAGGGTTAT  | TGTCTCATGA  | GCGGATACAT | ATTTGAATGT  | 5940 |
|    | ATTTAGAAAA | ATAAACAAAT | AGGGGTTCCG  | CGCACATTTT  | CCCGAAAAGT | GCCACCTGAC  | 6000 |
| 30 | GTCTAAGAAA | CCATTATTAT | CATGACATTA  | ACCTATAAAA  | ATAGGCGTAT | CACGAGGCCC  | 6060 |
|    | TTTCGTCTTC | AA         |             |             |            |             | 6072 |

**CLAIMS:**

1. A humanized antibody, wherein the complementary determining regions (CDRs) of a non-human antibody are grafted onto a human framework comprising the V<sub>L</sub>κ subgroup I (V<sub>L</sub>κI) and V<sub>H</sub> subgroup III (V<sub>H</sub> III), wherein of the V domain, at least one of representatively numbered residues 4 and 71 are substituted with an amino acid which differs from the amino acid at that position, and of the V<sub>H</sub> domain, at least three of representatively numbered residues 24, 37, 67, 69, 71, 73, 75, 76, 78, 93 and 94 are substituted with an amino acid which differs from the amino acid at that position.

5
2. The humanized antibody of claim 1, wherein the antibody is to vascular endothelial growth factor.

10
3. The humanized antibody of claim 2, wherein the V<sub>L</sub> domain has the sequence set forth in SEQ ID NO: 8 and the V<sub>H</sub> domain has the sequence set forth in SEQ ID NO: 11.
4. The humanized antibody of Claim 3, wherein residue 46, leucine, of SEQ ID NO: 8 is substituted by valine.

15
5. The humanized antibody of Claim 3, wherein in SEQ ID NO: 8, residue 4, methionine, is substituted by leucine and residue 71, tyrosine, is substituted with phenylalanine; and in SEQ ID NO: 11, residue 67, phenylalanine, is substituted by threonine.

20
6. The humanized antibody of claim 2, wherein the V<sub>L</sub> domain has the sequence set forth in SEQ ID NO: 7 and the V<sub>H</sub> domain has the sequence set forth in SEQ ID NO: 10, wherein in SEQ ID NO: 7, residue 71, phenylalanine, is substituted by tyrosine, and in SEQ ID NO: 10, residue 37, valine, is substituted by isoleucine, residue 78, leucine, is substituted by valine, and residue 94, arginine, is substituted by lysine.

25
7. The humanized antibody of claim 6, wherein in SEQ ID NO: 7, residue 4, methionine, is substituted by leucine.

30



8. The humanized antibody of claim 7, wherein in SEQ ID NO: 7, residue 71, tyrosine, is substituted by phenylalanine and wherein in SEQ ID NO: 10, residue 67, phenylalanine, is substituted by threonine.

5 9. A method of humanizing a non-human antibody comprising the steps of:

grafting complementary determining regions (CDRs) of a non-human antibody onto a human framework comprising the  $V_L$ κ subgroup I ( $V_L$ κI) and  $V_H$  subgroup III ( $V_H$  III); substituting in the  $V_L$  domain, at least one of residues 4 and 71 by an amino acid that is different from the amino acid at that position;

10 substituting in the  $V_H$  domain, at least three of residues 24,37,67,69,71,73,75, 76, 78, 93 and 94 by an amino acid that is different from the amino acid at that position.

10. The method of claim 9, wherein the antibody is for vascular endothelial growth factor.

15 11. The method of claim 10, wherein the  $V_L$  domain has the sequence set forth in SEQ ID NO: 8 and the  $V_H$  domain has the sequence set forth in SEQ ID NO: 11.

12. The method of claim 11, wherein residue 46, leucine, of SEQ ID NO: 8 is substituted by valine.

20

13. The method of claim 11, wherein in SEQ ID NO: 8, residue 4, methionine, is substituted by leucine and residue 71, tyrosine, is substituted by phenylalanine; and in SEQ ID NO: 11, residue 67, phenylalanine, is substituted by threonine.

25 14. The method of claim 10, wherein the  $V_L$  domain has the sequence set forth in SEQ ID NO: 7 and the  $V_H$  domain has the sequence set forth in SEQ ID NO: 10, wherein in SEQ ID NO: 7, residue 71, phenylalanine, is substituted by tyrosine, and in SEQ ID NO: 10, residue 37, valine, is substituted by isoleucine, residue 78, leucine, is substituted by valine, and residue 94, arginine, is substituted by lysine.

30

15. The method of claim 14, wherein in SEQ ID NO: 7, residue 4, methionine, is substituted by leucine.

16. The method of claim 15, wherein in SEQ ID NO: 7, residue 71, tyrosine, is substituted by phenylalanine.

17. The method of claim 10 further comprising the steps of:

- 5        displaying the  $V_L$  and  $V_H$  domains by substitutions on a phagemid;  
         determining whether VEGF will bind to the  $V_L$  and  $V_H$  domains by  
         substitutions;  
         selecting humanized antibodies which will bind to VEGF.

10    18. A method for inhibiting tumor growth by inhibiting mitogenic signaling comprising administering the humanized antibody of claim 1 to a tumor.

15    19. The humanized antibody of Claim 1 wherein the antibody is encoded by a nucleic acid molecule which hybridizes under high stringency conditions to a nucleic acid molecule having the sequence set forth in SEQ ID NO: 14.

20. The humanized antibody of Claim 1 encoded by a nucleic acid molecule having the sequence set forth in SEQ ID NO: 14.

1 / 3

 $V_L$  domain

|        |                                           |     |     |     |
|--------|-------------------------------------------|-----|-----|-----|
|        | 10                                        | 20  | 30  | 40  |
| A4.6.1 | DIQMTQTSSLSASLGDRVIISCSASQDISNYLNWYQQKP   |     |     |     |
|        | **                                        | *   | * * |     |
| hu2.0  | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP  |     |     |     |
| hu2.10 | DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP  |     |     |     |
|        |                                           |     |     |     |
|        | 50                                        | 60  | 70  | 80  |
| A4.6.1 | DGTVKVLIIYFTSSLHSGVPSRFSGSGSGTDYSLTISNLEP |     |     |     |
|        | **** *                                    |     | **  | * * |
| hu2.0  | GKAPKLLIIYFTSSLHSGVPSRFSGSGSGTDFTLTISLQP  |     |     |     |
| hu2.10 | GKAPKLLIIYFTSSLHSGVPSRFSGSGSGTDYTLTISLQP  |     |     |     |
|        |                                           |     |     |     |
|        | 90                                        | 100 |     |     |
| A4.6.1 | EDIATYYCQQYSTVPWTFGGGKLEIK                |     |     |     |
|        | *                                         | * * |     |     |
| hu2.0  | EDFATYYCQQYSTVPWTFGQGTKVEIK               |     |     |     |
| hu2.10 | EDFATYYCQQYSTVPWTFGQGTKVEIK               |     |     |     |

 $V_H$  domain

|        |                                            |       |           |     |
|--------|--------------------------------------------|-------|-----------|-----|
|        | 10                                         | 20    | 30        | 40  |
| A4.6.1 | EIQLVQSGPELKQPGETVRISCKASGYTFTNYGMNWVKQA   |       |           |     |
|        | * * * * *                                  | *** * |           | *   |
| hu2.0  | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA   |       |           |     |
| hu2.10 | EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWIRQA   |       |           |     |
|        |                                            |       |           |     |
|        | 50 a                                       | 60    | 70        | 80  |
| A4.6.1 | PGKGLKWMGWINTYTGEPTYAADFKRRFTFSLETSASTAYL  |       |           |     |
|        | * *                                        |       | * * * * * |     |
| hu2.0  | PGKGLEWVGWINTYTGEPTYAADFKRRFTISRDN SKNTLYL |       |           |     |
| hu2.10 | PGKGLEWVGWINTYTGEPTYAADFKRRFTISLDTSASTVYL  |       |           |     |
|        |                                            |       |           |     |
|        | abc                                        | 90    | 100abcdef | 110 |
| A4.6.1 | QISNLKNDTATYFCAKYPHYYGSSHWYFDVWGAGTTVTVSS  |       |           |     |
|        | *** * *                                    | * * * |           | * * |
| hu2.0  | QMNSLRAEDTAVYYCARYPHYYGSSHWYFDVWGQGLTVTVSS |       |           |     |
| hu2.10 | QMNSLRAEDTAVYYCARYPHYYGSSHWYFDVWGQGLTVTVSS |       |           |     |

**FIG. 1**





FIG. 2

3 / 3

**FIG. 3**




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07K 16/22, C12N 15/13, 15/63, 15/70, A61K 39/395</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | <b>A3</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | (11) International Publication Number: <b>WO 98/45332</b>       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (43) International Publication Date: 15 October 1998 (15.10.98) |
| (21) International Application Number: <b>PCT/US98/06724</b><br>(22) International Filing Date: <b>3 April 1998 (03.04.98)</b><br>(30) Priority Data:<br>08/833,504                      7 April 1997 (07.04.97) <b>US</b><br>(71) Applicant (for all designated States except US): <b>GENENTECH, INC. [US/US]; One DNA Way, South San Francisco, CA 94080 (US).</b><br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): <b>WELLS, James, A. [US/US]; 1341 Columbus Avenue, Burlingame, CA 94010 (US). BACA, Manuel [AU/US]; Apartment #H3, 888 Foster City Boulevard, Foster City, CA 94404 (US). PRESTA, Leonard, G. [US/US]; Apartment 206, 1900 Gough, San Francisco, CA 94109 (US).</b><br>(74) Agents: <b>DREGER, Walter, H. et al.; Flehr, Hohbach, Test, Albritton &amp; Herbert LLP, Suite 3400, 4 Embarcadero Center, San Francisco, CA 94111-4187 (US).</b> |  | (81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b><br><b>Published</b><br><i>With international search report.</i><br>(88) Date of publication of the international search report: <b>3 December 1998 (03.12.98)</b> |                                                                 |

(54) Title: **HUMANIZED ANTIBODIES AND METHODS FOR FORMING HUMANIZED ANTIBODIES**

## (57) Abstract

Described herein is a humanized antibody to vascular endothelial growth factor (VEGF). Also described herein is a method for rapidly producing and identifying framework mutations which improve the binding of humanized antibodies to their cognate antigens. In a preferred embodiment, non-human CDRs are grafted onto a human V<sub>L</sub>κI-V<sub>H</sub>III framework. Random mutagenesis of a small set of critical framework residues is also performed followed by monovalent display of the resultant library of antibody molecules on the surface of filamentous phage. The optimal framework sequences are then identified by affinity-based selection. Optionally, the selected antibodies can be further mutated so as to replace vernier residues which sit at the V<sub>L</sub>-V<sub>H</sub> interface by residues which match the non-human parent antibody. The methods described herein can be applied to any non-human antibody. Accordingly, humanized antibodies are provided.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                          |    |                                              |    |                          |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   | ML | Mali                                         | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | MN | Mongolia                                     | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MR | Mauritania                                   | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MW | Malawi                                       | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MX | Mexico                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | NE | Niger                                        | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NL | Netherlands                                  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NO | Norway                                       | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NZ | New Zealand                                  | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | PL | Poland                                       |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CN | China                    | KZ | Kazakhstan                               | RO | Romania                                      |    |                          |
| CU | Cuba                     | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                            | SD | Sudan                                        |    |                          |
| DE | Germany                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| DK | Denmark                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |
| EE | Estonia                  |    |                                          |    |                                              |    |                          |



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06724

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K16/22 C12N15/13 C12N15/63 C12N15/70 A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                               | Relevant to claim No. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X        | WO 92 22653 A (GENENTECH INC)<br>23 December 1992                                                                                                                                                                                                                | 3, 11                 |
| Y        | the whole document and specially: see<br>SEQ.ID.N. 17 and 18<br>see page 5, line 24 - page 7, line 35<br>see page 9, line 22 - page 10, line 4;<br>figure 5                                                                                                      | 1, 2, 9, 10           |
| Y        | ---<br>KIM ET AL.,: "Inhibition of vascular<br>endothelial growth factor-induced<br>angiogenesis suppresses tumor growth in<br>vivo"<br>NATURE,<br>vol. 362, 1993, page 841 XP002013864<br>London, GB<br>cited in the application<br>see abstract<br>---<br>-/-- | 1, 2, 9, 10           |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 September 1998

Date of mailing of the international search report

02/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/06724

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                       | Relevant to claim No. |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A        | US 5.580 723 A (WELLS JAMES A ET AL) .<br>3 December 1996<br>see figures 12A-J<br>---                                                                                                                                    | 19,20                 |
| A        | WO 94 04679 A (GENENTECH INC) 3 March 1994<br>see page 1-73<br>---                                                                                                                                                       | 1,9                   |
| A        | GB 2 268 744 A (CELLTECH LTD)<br>19 January 1994<br>see abstract<br>see page 4, paragraph 3 - page 6,<br>paragraph 1<br>---                                                                                              | 1,9                   |
| A        | M.M. BENDIG: "Humanization of rodent<br>monoclonal antibodies"<br>METHODS: A COMPANION TO METHODS IN<br>ENZYMOLOGY,<br>vol. 8, 1995, pages 83-93, XP000647344<br>New York, NY, US<br>see the whole document<br>---       | 1,10                  |
| P,X      | M. BACA ET AL., : "Antibody humanization<br>using monovalent phage display"<br>JOURNAL OF BIOLOGICAL CHEMISTRY,<br>vol. 272, no. 16, 18 April 1997, pages<br>10678-10684, XP002077471<br>see the whole document<br>----- | 1-14                  |

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/06724

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| WO 9222653 A                              | 23-12-1992          | AU 675916 B                | 27-02-1997          |
|                                           |                     | AU 2250992 A               | 12-01-1993          |
|                                           |                     | CA 2103059 A               | 15-12-1992          |
|                                           |                     | EP 0590058 A               | 06-04-1994          |
|                                           |                     | JP 6508267 T               | 22-09-1994          |
|                                           |                     | WO 9404679 A               | 03-03-1994          |
| US 5580723 A                              | 03-12-1996          | US 5766854 A               | 16-06-1998          |
|                                           |                     | US 5534617 A               | 09-07-1996          |
|                                           |                     | EP 0397834 A               | 22-11-1990          |
|                                           |                     | JP 4502454 T               | 07-05-1992          |
|                                           |                     | WO 9004788 A               | 03-05-1990          |
|                                           |                     | CA 2001774 A               | 28-04-1990          |
|                                           |                     | US 5688666 A               | 18-11-1997          |
| WO 9404679 A                              | 03-03-1994          | AU 675916 B                | 27-02-1997          |
|                                           |                     | AU 2250992 A               | 12-01-1993          |
|                                           |                     | EP 0590058 A               | 06-04-1994          |
|                                           |                     | JP 6508267 T               | 22-09-1994          |
|                                           |                     | CA 2103059 A               | 15-12-1992          |
|                                           |                     | WO 9222653 A               | 23-12-1992          |
|                                           |                     | AU 5083193 A               | 15-03-1994          |
| GB 2268744 A                              | 19-01-1994          | AT 129017 T                | 15-10-1995          |
|                                           |                     | AT 124459 T                | 15-07-1995          |
|                                           |                     | AT 159299 T                | 15-11-1997          |
|                                           |                     | AU 664801 B                | 30-11-1995          |
|                                           |                     | AU 6461294 A               | 22-12-1994          |
|                                           |                     | AU 646009 B                | 03-02-1994          |
|                                           |                     | AU 6974091 A               | 24-07-1991          |
|                                           |                     | AU 649645 B                | 02-06-1994          |
|                                           |                     | AU 7033091 A               | 24-07-1991          |
|                                           |                     | AU 631481 B                | 26-11-1992          |
|                                           |                     | AU 7048691 A               | 24-07-1991          |
|                                           |                     | BG 60462 B                 | 28-04-1995          |
|                                           |                     | CA 2037607 A               | 07-09-1992          |
|                                           |                     | CA 2046904 A               | 22-06-1991          |
|                                           |                     | CA 2050479 A,C             | 22-06-1991          |
|                                           |                     | DE 69020544 D              | 03-08-1995          |
|                                           |                     | DE 69020544 T              | 18-01-1996          |

Information on patent family members

International Application No

PCT/US 98/06724

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|-------------------------------------------|---------------------|----------------------------|---------------------|
| GB 2268744 A                              |                     | DE 69022982 D              | 16-11-1995          |
|                                           |                     | DE 69022982 T              | 28-03-1996          |
|                                           |                     | DE 69031591 D              | 20-11-1997          |
|                                           |                     | DE 69031591 T              | 12-03-1998          |
|                                           |                     | DK 460167 T                | 20-11-1995          |
|                                           |                     | DK 460171 T                | 28-08-1995          |
|                                           |                     | DK 460178 T                | 22-12-1997          |
|                                           |                     | EP 0460167 A               | 11-12-1991          |
|                                           |                     | EP 0460171 A               | 11-12-1991          |
|                                           |                     | EP 0460178 A               | 11-12-1991          |
|                                           |                     | EP 0620276 A               | 19-10-1994          |
|                                           |                     | EP 0626390 A               | 30-11-1994          |
|                                           |                     | ES 2079638 T               | 16-01-1996          |
|                                           |                     | ES 2074701 T               | 16-09-1995          |
|                                           |                     | ES 2112270 T               | 01-04-1998          |
|                                           |                     | WO 9109966 A               | 11-07-1991          |
|                                           |                     | WO 9109967 A               | 11-07-1991          |
|                                           |                     | WO 9109968 A               | 11-07-1991          |
|                                           |                     | GB 2246781 A,B             | 12-02-1992          |
|                                           |                     | GB 2246570 A,B             | 05-02-1992          |
|                                           |                     | GB 2268745 A,B             | 19-01-1994          |
|                                           |                     | GR 3017734 T               | 31-01-1996          |
|                                           |                     | GR 3025781 T               | 31-03-1998          |
|                                           |                     | JP 4505398 T               | 24-09-1992          |
|                                           |                     | JP 4506458 T               | 12-11-1992          |
|                                           |                     | JP 5500312 T               | 28-01-1993          |